Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
Healthcare
$32.43 +0.74%
+$0.18 today
- Market cap
- $1.77B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
52W Low $9.83High $53.65
Volume 1.00M
Average 0.84M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$142.90M
FY 2025 · Annual
Net Income
-$131.12M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| 43.78M | 43.78M | 43.8M | 42.98M | |
| 43.78M | 43.78M | 43.8M | 42.98M |
MAZE Earnings Waterfall · TTM
NASDAQ:MAZE · Revenue to Net Income
Key Ratios
EPS$-2.75
Gross Margin24.4%
Net Margin-30.3%
P/E Ratio-10.8
P/S Ratio20.1
Analysis
$20.0M of revenue converted into -$122.5M of net income for the selected period. Gross margin is 24.4% and net margin is -30.3%, showing how much revenue survives after costs and taxes. EPS is $-2.75, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 8-K | Current report | Oct 16, 2026 |
How much revenue does MAZE generate?
Maze Therapeutics, Inc. (MAZE) reported $0.00 of revenue in fiscal 2025.
Is MAZE profitable?
Maze Therapeutics, Inc. (MAZE) reported -$131.12M of net income.
Continue the stock analysis
Jump to another research area for this company.